In Business 32 Years - Since 1980
THE CURRENT TIME at LC Labs is:
|
|
||||||
In Business 32 Years - Since 1980 |
THE CURRENT TIME at LC Labs is: |
|||||
|
 |
 |
|
Size |
US $ |
€ |
£ |
¥ |
|
||
|
10 mg |
55 |
42 |
35 |
4200 |
| ||
|
25 mg |
78 |
59 |
49 |
6000 |
| ||
|
50 mg |
139 |
106 |
88 |
10700 |
| ||
|
100 mg |
238 |
181 |
150 |
18200 |
| ||
|
200 mg |
445 |
338 |
281 |
34100 |
| ||
|
1 g |
1495 |
1136 |
945 |
114600 |
| ||
Note: Our Euro, Pound, and Yen prices are revised regularly to account for currency exchange rate fluctuations.
| Compare Quality and Prices — LC Labs vs. Other Suppliers |
|---|
M.W. 404.32
C19H12F4N4O2
[745833-23-2]
Storage: Store at or below -20 ºC. Solubility: Soluble in DMSO. Disposal: A
Find and View a Certificate of Analysis for this product
View the MSDS for this product
VX-702 is a second-generation, orally active mitogen-activated protein kinase (MAPK) p38 inhibitor. It is being tested for the potential treatment of inflammation, rheumatoid arthritis and cardiovascular diseases. Ding, C. "Drug evaluation: VX-702, a MAP kinase inhibitor for rheumatoid arthritis and acute coronary syndrome." Curr. Opin. Investig. Drugs 7: 1020-1025 (2006).
p38 MAPK increases thromboxane levels by activating phospholipase A2, thus catalyzing the formation of arachidonic acid. VX-702 inhibited activation of p38 MAPK by thrombin, SFLLRN, AYPGKF and U46619 in platelets. Kuliopulos, A., et al. "Effect of selective inhibition of the p38 MAP kinase pathway on platelet aggregation." Thromb. Haemost. 92: 1387-1393 (2004).
VX-702 showed modest clinical efficacy and transient suppression of biomarkers of inflammation in patients with rheumatoid arthritis. Damjanov, N., et al. "Efficacy, pharmacodynamics, and safety of VX-702, a novel p38 MAPK inhibitor, in rheumatoid arthritis: results of two randomized, double-blind, placebo-controlled clinical studies." Arthritis Rheum. 60: 1232-1241 (2009).
Another CAS number previously assigned to VX-702, 479543-46-9, has been deleted by CAS and is no longer in use.
Sold for laboratory or manufacturing purposes only; not for human, medical, veterinary, food, or household use.
This product is offered for R&D use in accordance with (i) 35 USC 271(e)+A13(1) in the U.S.; (ii) Section 69.1 of Japanese Patent Law in Japan; (iii) Section 11, No. 2 of the German Patent Act of 1981 in Germany; (iv) Section 60, Paragraph 5b of the U.K. Patents Act of 1977 in the U.K.; (v) Sections 55.2(1) and 55.2(6) and other common law exemptions of Canadian patent law; (vi) Section 68B of the Patents Act of 1953 in New Zealand together with the amendment of same by the Statutes Amendment Bill of 2002; (vii) such related legislation and/or case law as may be or become applicable in the aforementioned countries; and (viii) such similar laws and rules as may apply in various other countries.
Not available in some countries; not available to some institutions; not available for some uses.
Our products are for laboratory research only and are sold only to qualified research institutions, not to individuals or patients nor for veterinary use.
